BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.55
-0.39 (-3.92%)
At close: Jun 29, 2026, 4:00 PM EDT
9.55
0.00 (0.00%)
Pre-market: Jun 30, 2026, 6:01 AM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 435 employees as of December 31, 2025. The number of employees decreased by 145 or -25.00% compared to the previous year.
Employees
435
Change (1Y)
-145
Growth (1Y)
-25.00%
Revenue / Employee
$2,036,129
Profits / Employee
-$1,052,834
Market Cap
2.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | -145 | -25.00% |
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| HUTCHMED (China) | 1,796 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
| Harrow | 373 |
BCRX News
- 22 hours ago - BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs - Reuters
- 23 hours ago - BioCryst to discontinue internal discovery programs, close Alabama facility - TheFly
- 23 hours ago - BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility - GlobeNewsWire
- 17 days ago - BioCryst to present new Orladeyo data at EAACI - TheFly
- 17 days ago - BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 20 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire